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Study objective: To examine the efficacy and safety of the once-daily, inhaled, long-acting
muscarinic antagonist/b2-agonist combination umeclidinium/vilanterol (UMEC/VI) compared
with UMEC and VImonotherapies in patients with chronic obstructive pulmonary disease (COPD).
Methods: In this 24-week, double-blind, placebo-controlled, parallel-group study
(ClinicalTrials.gov: NCT01313650) eligible patients were randomised 3:3:3:2 to treatment with
UMEC/VI 62.5/25 mcg, UMEC 62.5 mcg, VI 25 mcg or placebo administered once daily via dry
powder inhaler (N Z 1532; intent-to-treat population). Primary endpoint was trough forced
expiratory volume in one second (FEV1) on Day 169 (23e24 h post-dose). Additional lung-
function, symptomatic, and health-related quality-of-life endpoints were assessed, including
0e6 h weighted-mean FEV1, rescue salbutamol use, Transition Dyspnoea Index (TDI), Shortness
Of BreathWith Daily Activity (SOBDA) and St. George’s Respiratory Questionnaire (SGRQ) scores.
Safety evaluations included adverse events (AEs), vital signs, 12-lead/24-h Holter electrocardi-
ography parameters and clinical laboratory/haematology measurements.
Results: All active treatments produced statistically significant improvements in trough FEV1
compared with placebo on Day 169 (0.072e0.167 L, all p < 0.001); increases with UMEC/VI
62.5/25 mcg were significantly greater than monotherapies (0.052e0.095 L, p  0.004).
Improvements were observed for UMEC/VI 62.5/25 mcg vs placebo for weighted-mean FEV19 966 2531; fax: þ1 919 966 7013.
ed.unc.edu (J.F. Donohue).
3 Elsevier Ltd. All rights reserved.
13.06.001
Efficacy and safety of UMEC/VI in patients with COPD 1539on Day 168 (0.242 L, p < 0.001), rescue salbutamol use during Weeks 1e24 (0.8 puffs/day,
pZ 0.001), TDI (1.2 units, p < 0.001), SOBDA (0.17 units, p < 0.001) and SGRQ (5.51 units,
p < 0.001) scores. No clinically-significant changes in vital signs, electrocardiography, or labo-
ratory parameters were observed.
Conclusion: Once-daily UMEC/VI 62.5/25 mcg was well tolerated and provided clinically-
significant improvements in lung function and symptoms in patients with COPD.
ª 2013 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is a
preventable and treatable disease characterised by
persistent airflow limitation [1,2]. Bronchodilators are
central to the pharmacological management of COPD and
include muscarinic antagonists and b2-agonists [2]. Musca-
rinic antagonists act by binding to the M3 receptor subtype
localised in airway smooth muscle, thereby blocking
the bronchoconstrictive response to cholinergic nervous
stimulation and facilitating airway smooth muscle relaxa-
tion [3,4]. b2-agonists stimulate b2-adrenergic receptors,
increasing cyclic adenosine monophosphate and facilitating
smooth muscle relaxation [4]. These two distinct and
complementary mechanisms of inducing bronchodilation
provide opportunities for combination long-acting
bronchodilator therapies that may improve treatment
efficacy. Long-acting agents may also improve compliance
due to the convenience of once-daily maintenance treat-
ment. Clinical studies support this rationale, with the co-
administration of long-acting muscarinic antagonists
(LAMA) and long-acting b2-agonists (LABA) demonstrating
significantly greater improvements in lung function
compared with individual treatments in patients with COPD
[4e11]. Further, a LAMA/LABA combination may be asso-
ciated with a lower risk of side effects compared with
increasing the dose of a single agent [2].
A fixed-dose combination of the orally inhaled LAMA,
umeclidinium bromide (UMEC) and the orally inhaled
LABA, vilanterol (VI), is currently in development as a
maintenance treatment for patients with COPD. Initial
dose-ranging studies showed that both agents were well
tolerated and significantly improved lung function
compared with placebo over 24 h in patients with COPD
[12,13].
Here we present the results of a large, placebo-
controlled study that examined the efficacy and safety of
once-daily UMEC/VI 62.5/25 mcg compared with UMEC
62.5 mcg, VI 25 mcg and placebo.Methods
Study design and treatments
This 24-week, randomised, double-blind, placebo-
controlled, multicentre, parallel-group study was
conducted in a total of 163 centres in 13 countries from 30
March 2011 to 5 April 2012 (ClinicalTrials.gov identifier:
NCT01313650; GSK study number: DB2113373). Furtherdetails are provided in Online Supplementary Materials.
Eligible patients with COPD were randomly assigned 3:3:3:2
to receive one of three active treatments: UMEC/VI 62.5/
25 mcg (delivering 55/22 mcg), UMEC 62.5 mcg (delivering
55 mcg), VI 25 mcg (delivering 22 mcg) or placebo. The
randomisation ratio allowed for additional exposure to
the active treatments compared with placebo, for the
evaluation of safety. All treatments were administered
once daily as a single inhalation in the morning, delivered
via a dry powder inhaler (DPI).
A central randomisation schedule was generated using a
validated computerised system (RandAll). Patients were
randomised using an automated, interactive telephone-
based system that registered and randomised medication
assignment. Ten study outpatient visits were conducted
throughout the study (see Supplementary Materials).
Patients
Eligible patients were current or former cigarette smokers
aged 40 years with a clinically established history of
COPD characterised by airflow limitation that is not fully
reversible [1] and documented based on a smoking history
of 10 pack-years, had a post-salbutamol forced expiratory
volume in one second (FEV1)/forced vital capacity (FVC)
ratio of <0.70 and a post-salbutamol FEV1 of 70% of pre-
dicted normal values (calculated using the National Health
and Nutrition Examination Survey III) [14, 15] and had a
score of 2 on the modified Medical Research Council
Dyspnoea Scale [16]. Patients were excluded if they had a
current diagnosis of asthma or other known respiratory
disorders, including a-1 antitrypsin deficiency, active
tuberculosis, bronchiectasis, sarcoidosis, lung fibrosis,
pulmonary hypertension, interstitial lung disease, any
clinically significant uncontrolled disease (including
cardiovascular-related disease) as determined by the study
investigators, an abnormal and clinically significant elec-
trocardiogram (ECG) or 24-h Holter ECG (if conducted), or
significantly abnormal clinical laboratory finding. Concom-
itant use of inhaled salbutamol (albuterol) as rescue
medication was allowed. Inhaled corticosteroids (ICS) were
allowed at a stable dose of 1000 mcg/day of fluticasone
propionate or equivalent from 30 days prior to screening
onward. Other permitted and prohibited medications are
provided in the Online Supplement.
All patients provided written informed consent prior to
study participation. The study was approved by local ethics
review committees and was conducted in accordance with
the Declaration of Helsinki and Good Clinical Practice
guidelines (WMA Declaration of Helsinki, 2008).
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Lung function
The primary efficacy endpoint was pre-dose trough FEV1 on
treatment Day 169, defined as the mean of FEV1 values
obtained 23 h and 24 h after dosing on Day 168 (Week 24
visit). Secondary and additional lung function endpoints
were: weighted mean FEV1 over 0e6 h post-dose on Day 168;
trough and 0e6 h weighted mean FEV1 at other visits, serial
FEV1 assessments, time to onset during 0e6 h post-dose on
Day 1, proportion of patients achieving an increase in FEV1 of
12% and 0.2 L above baseline at any time during 0e6 h
post-dose on Day 1, proportion of patients achieving an in-
crease of 0.1 L above baseline in trough FEV1, peak FEV1
and serial and trough FVC. Serial FEV1 over 0e24 h post-dose
was obtained in a subset of patients to characterise changes
in lung function over the dosing interval.
FEV1 and FVC were obtained using standard spirometry
equipment that met or exceeded the minimal ATS
performance recommendations [17] and reported as
least squares means (LS) change from baseline. At
screening, responsiveness to salbutamol (4 puffs, approxi-
mately 360 mcg) was obtained. To further characterise
bronchodilator responsiveness, post-ipratropium (4 puffs,
approximately 72 mcg) testing was conducted following
completion of post-salbutamol spirometry.
Other outcomes
Other outcomes included: mean Transition Dyspnoea Index
(TDI) focal score [18]; mean Shortness Of Breath With Daily
Activity (SOBDA) score [19]; rescue salbutamol use, time to
first COPD exacerbation and the St. George’s Respiratory
Questionnaire (SGRQ) score to assess impact on the
health-related quality of life [20]. An exacerbation wasUMEC/VI 62.5/25 mcg
N=413
Completed n=332 (80%)
Withdrew n=81 (20%)
Adverse event, 23 (6%); 
lack of efficacy, 20 (5%); 
protocol deviation, 6 (1%); 
reached stop criteria, 15 (4)%; 
lost to follow-up, 2 (<1%); 
withdrew consent, 15 (4%)
Intent-to-trea
N=153
Randomi
N=153
All subjects
N=221
UMEC 62.5 mcg
N=418
Completed n=324 (78%)
Withdrew n=94 (22%)
Adverse event, 34 (8%); 
lack of efficacy, 20 (5%); 
protocol deviation, 7 (2%); 
reached stop criteria, 13 (3%); 
withdrew consent, 20 (5%)
Figure 1 Patient disposition and flow diagram. Note: Some patien
did not have a Day 169 Visit or did not complete Day 169; others a
were not classed as completers by the reporting investigator. Patie
last clinic visit excluding follow-up (Visit 9) and did not withdrawdefined as an acute worsening of symptoms of COPD
requiring emergency treatment, hospitalisation or the use
of additional pharmacotherapy beyond the study drug or
rescue salbutamol (e.g. oral steroids and antibiotics).
Plasma pharmacokinetic (PK) samples were collected at
multiple visits for population PK analysis, to be reported
elsewhere.
Safety
Safety evaluations included the incidence of adverse events
(AEs), vital signs (systolic and diastolic blood pressure, and
pulse rate), 12-lead ECG in all patients and 24-h Holter ECG
monitoring obtained in a subset of patients, clinical
chemistry and haematology.
Statistical analyses
Sample size was calculated to provide sufficient power for
the primary endpoint, as well as the TDI as a symptomatic
endpoint, and assumed a two-sided 5% significance level.
Further details are provided in the Online Supplementary
Materials. The primary analyses were performed on
the intent-to-treat (ITT) population, defined as all
randomised patients who had received at least one dose
of the double-blind study medication. The primary analyses
of the primary and secondary endpoints were performed
using mixed-models repeated-measures (MMRM) with
covariates of: baseline FEV1, smoking status, day, centre
grouping, treatment, day-by-baseline interaction and
day-by-treatment interaction, where day was nominal. The
analysis of TDI as a symptomatic endpoint used Baseline
Dyspnoea Index score in place of baseline FEV1. To account
for multiplicity across treatment comparisons and end-
points, a step-down closed testing procedure was used.Screening or run-in failures 
n=678
(Screening failures: did not meet inclusion/exclusion 
criteria, 547; adverse event, 1; withdrew consent, 36. 
Run-in failures: adverse event, 2; study closed/terminated, 4;
withdrew consent, 21; did not meet 
continuation criteria, 67)
Patients randomised in error who
did not receive study drug
n=4
t (ITT)
2
sed
6
 enrolled
0
VI 25 mcg
N=421
Completed n=318 (76%)
Withdrew n=103 (24%)
Adverse event, 24 (6%); 
lack of efficacy, 32 (8%); 
protocol deviation, 5 (1%); 
reached stop criteria, 24 (6)%; 
lost to follow-up, 3 (<1%); 
withdrew consent, 15 (4%)
Placebo
N=280
Completed n=204 (73%)
Withdrew n=76 (27%)
Adverse event, 9 (3%); 
lack of efficacy, 37 (13%); 
protocol deviation, 4 (1%); 
reached stop criteria, 9 (3%); 
lost to follow-up, 1 (<1%); 
withdrew consent, 16 (6%)
ts were classed by the reporting investigator as completers but
ttended a Day 169 Visit or completed Day 169 assessments but
nts were considered to have completed if they completed the
at that visit.
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for the 24-h Holter analysis subset was selected to provide a
descriptive evaluation of the 24-h serial FEV1 profiles and to
allow for additional assessment of cardiovascular safety
using 24-h Holter monitoring.Results
Patients
Of 2210 patients screened, 1532 patients were included in
the ITT population. In total, 1178 patients completed the
study and 197 patients were included in the 24-h Holter/24-h
serial FEV1 subset; patient disposition and reasons for
discontinuation are shown in Fig. 1. Across the groups,
58e64% of patients reported having a cardiovascular
related current medical condition and 49e52% of patients
used ICS.
Patient demographics and baseline characteristics are
shown in Table 1 and were similar across treatment groups
and consistent with moderate-to-severe COPD.Table 1 Patient demographics and baseline characteristics (int
Placebo
(N Z 280)
UMEC 62.
(N Z 418
Age (y)
Mean (SD) 62.2 (9.04) 64.0 (9.1
Sex
Female n (%) 85 (30) 120 (29)
Male n (%) 195 (70) 298 (71)
Current smoker at screeninga
n (%) 150 (54) 207 (50)
Smoking pack-years
Mean (SD) 47.2 (27.21) 46.8 (27.
ICS use at screening
n (%) 137 (49) 219 (52)
Post-salbutamol % predicted FEV1
Mean (SD) 46.7 (12.71) 46.8 (13.
Post-salbutamol FEV1/FVC
Mean (SD) 47.1 (11.47) 46.8 (11.
GOLD stage
n 280 417
II, n (%) 119 (43) 191 (46)
III, n (%) 133 (48) 172 (41)
IV, n (%) 28 (10) 54 (13)
% reversibility to salbutamol
Mean (SD) 15.3 (15.54) 13.9 (14.
% reversibility to salbutamol and ipratropiumb
Mean (SD) 22.7 (19.61) 22.3 (18.
Reversible to salbutamol
n (%) 91 (33) 121 (29)
Reversible to salbutamol and ipratropium
n (%) 146 (54) 223 (54)
FEV1, forced expiratory volume in one second; FVC, forced vital capac
ICS, inhaled corticosteroid; SD, standard deviation.
a Reclassified: patient reclassified as current smoker if smoked with
b Reversibility to salbutamol and ipratropium was defined as an incr
salbutamol and ipratropium.Efficacy outcomes
Lung function
Lung function outcomes are summarised in Supplementary
Table 1. Statistically significant improvements in trough
FEV1 at Day 169 were observed for UMEC/VI 62.5/25 mcg,
UMEC 62.5 mcg and VI 25 mcg compared with placebo
([difference; p-value] 0.167 L, 0.115 L, and 0.072 L; all
p < 0.001) (Fig. 2a, Supplementary Table 1). Statistically
significant improvements were also demonstrated for UMEC/
VI 62.5/25 mcg compared with UMEC 62.5 mcg (0.052 L;
pZ 0.004) and VI 25 mcg at Day 168 (0.095 L; p < 0.001).
Greater increases from baseline in 0e6 h weighted mean
FEV1 at Day 168 were also observed with UMEC/VI 62.5/
25 mcg, UMEC 62.5 mcg and VI 25 mcg compared with
placebo (0.242 L, 0.150 L and 0.122 L; all p < 0.001)
(Fig. 2b). Similarly, greater increases were observed for
UMEC/VI 62.5/25 mcg compared with UMEC 62.5 mcg
(0.092 L; p < 0.001) and VI 25 mcg (0.120 L; p < 0.001) at
Day 168.
In the subset of patients with serial spirometry over 24 h,
improvements in serial FEV1 values were obtained withent-to-treat population).
5
)
VI 25
(N Z 421)
UMEC/VI 62.5/25
(N Z 413)
6) 62.7 (8.52) 63.1 (8.71)
136 (32) 108 (26)
285 (68) 305 (74)
199 (47) 203 (49)
03) 44.7 (23.16) 46.5 (25.80)
212 (50) 212 (51)
39) 48.2 (13.27) 47.8 (13.19)
07) 47.4 (11.49) 48.0 (11.42)
420 412
197 (47) 201 (49)
179 (43) 166 (40)
44 (10) 45 (11)
92) 15.7 (15.57) 13.9 (15.06)
51) 23.6 (19.42) 22.2 (18.82)
155 (37) 129 (31)
230 (56) 227 (56)
ity; GOLD, Global Initiative for Chronic Obstructive Lung Disease;
in 6 months.
ease in FEV1 of 12% and 0.2 L following administration of both
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Figure 2 Measurement of lung function: least squares (LS)
mean (95% confidence interval [CI]) change from baseline in (a)
trough forced expiratory volume in one second (FEV1, L) and
(b) 0e6 h weighted mean FEV1 (L, intent-to-treat population).
UMEC Z umeclidinium bromide; VI Z vilanterol. Analysis
performed using a repeated measures model with covariates of
treatment, baseline, smoking status, center group, Day, day by
baseline, and Day by treatment interactions.
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Figure 3 Serial trough forced expiratory volume in one
second (FEV1, L): least squares (LS) mean (95% confidence
interval [CI]) change from baseline in FEV1 over time on Day 1,
84 and 168 (L, 24-h population). UMEC Z umeclidinium
bromide; VIZ vilanterol. Analysis performed using a repeated
measures model with covariates of treatment, baseline (mean
of the two FEV1 assessments made 30 and 5 min pre-dose on
Day 1), smoking status, center group, Day, Day by baseline, and
Day by treatment interactions.
1542 J.F. Donohue et al.UMEC/VI 62.5/25 mcg compared with UMEC 62.5 mcg, VI
25 mcg, and placebo for most timepoints (Fig. 3). In the ITT
population, on Day 1 UMEC/VI 62.5/25 mcg treatment
resulted in improvements in FEV1 after 15 min (first
assessment) compared with placebo (0.112 L; p < 0.001).
The median time to onset, defined as a post-dose
FEV1  0.1 L above baseline, during 0e6 h post-dose Day
1 was shorter with UMEC/VI 62.5/25 mcg and VI 25 mcg
(27 min and 31 min, respectively) compared with UMEC
62.5 mcg (56 min).
Peak FEV1 increases for UMEC/VI 62.5/25 mcg relative to
baseline over 6 h on Day 1 and Day 168 were 0.273 L and
0.320 L, respectively. UMEC/VI 62.5/25 mcg also provided
improvements in peak FEV1 compared with placebo, UMEC
62.5 mcg and VI 25 mcg at Day 168 (0.094e0.224 L; all
p < 0.001).
Improvements in trough FVC change from baseline were
observed at Day 169 for UMEC/VI 62.5/25 mcg, UMEC
62.5 mcg and VI 25 mcg compared with placebo (0.248 L,
0.175 L, and 0.105 L; all p  0.002). Improvements were
also demonstrated for UMEC/VI 62.5/25 mcg compared with
UMEC 62.5 mcg and VI 25 mcg (0.074 L and 0.143 L;
p Z 0.012 and p < 0.001, respectively) (Supplementary
Table 1).
Other efficacy outcomes
All active treatment groups increased TDI focal score at Day
168 and throughout the study compared with placebo
(Table 2, Fig. 4). At Days 28, 84 and 168, the odds of being aresponder according to TDI focal score (defined as
those with an improvement of 1 unit [21]) was higher for
UMEC/VI 62.5/25 mcg compared with VI 25 mcg (odds ratio
[OR] at all timepoints: 1.4; all p  0.038) and for all active
treatments compared with placebo (OR: 1.5e3.1; all
p  0.013).
At Week 24, UMEC/VI 62.5/25 mcg, UMEC 62.5 mcg and
VI 25 mcg were associated with improvements in SOBDA
score compared with placebo (Table 2).
Over the 24-week study period, all active treatments
resulted in less rescue salbutamol use compared with pla-
cebo (Table 2).
Health-related quality of life
All active treatments resulted in an improvement (i.e. a
reduction) in SGRQ score at Day 168 and a greater proportion
of patients demonstrated a clinically meaningful response in
SGRQ score compared with placebo. Improvements were
similar across active treatment groups (Table 2).
COPD exacerbations
On-treatment COPD exacerbations were reported in 13% of
patients in the placebo group and 7e9% in active treatment
groups. The analysis of time to first COPD exacerbation
indicated that UMEC/VI 62.5/25 mcg and UMEC 62.5 mcg
resulted in a lower risk of COPD exacerbation compared
with placebo (Table 2).
Table 2 Summary of additional efficacy measures.
Placebo
(N Z 280)
UMEC 62.5
(N Z 418)
VI 25
(N Z 421)
UMEC/VI 62.5/25
(N Z 413)
TDI focal score, Day 168
LS mean (SE) 1.2 (0.20) 2.2 (0.16) 2.1 (0.16) 2.4 (0.16)
Difference vs placebo, (95% CI) e 1.0* (0.5, 1.5) 0.9* (0.4, 1.4) 1.2* (0.7, 1.7)
UMEC/VI vs individual components, (95% CI) e 0.3 (0.2, 0.7) 0.4 (1.0, 0.8) e
Proportion of responders according to TDI focal score, Day 168
Responder n (%) 106 (41) 207 (53) 197 (51) 226 (58)
OR vs placebo, (95% CI) e 1.6y (1.2, 2.3) 1.5z (1.1, 2.1) 2.0* (1.5, 2.8)
SOBDA score, Week 24
LS mean change from baseline (SE) 0.06 (0.037) 0.16 (0.029) 0.21 (0.030) 0.23 (0.029)
Difference vs placebo, (95% CI) e 0.10z
(0.19, 0.00)
0.14y
(0.24, 0.05)
0.17*
(0.26, 0.08)
UMEC/VI vs individual Components, (95% CI) e 0.08
(0.16, 0.01)
0.03
(0.11, 0.05)
e
Proportion of respondersa according to SOBDA score, Week 24 (threshold [ L0.1)
Responder n (%) 52 (21) 112 (30) 109 (29) 121 (32)
OR vs placebo, (95% CI) e 1.7y (1.2, 2.5) 1.6z (1,1, 2.3) 1.8y (1.2, 2.6)
SGRQ score, Day 168
Change from baseline (SE) 2.56 (0.950) 7.25 (0.753) 7.75 (0.760) 8.07 (0.749)
Difference vs placebo, (95% CI) e 4.69*
(7.07, 2.31)
5.19*
(7.58, 2.80)
5.51*
(7.88, 3.13)
UMEC/VI vs individual Components, (95% CI) e 0.82
(2.90, 1.27)
0.32
(2.41, 1.78)
e
Proportion of respondersb according to SGRQ total score, Week 24
Responder n (%) 86 (34) 172 (44) 181 (48) 188 (49)
OR vs placebo, (95% CI) e 1.6y (1.2, 2.3) 1.9* (1.3, 2.6) 2.0* (1.4, 2.8)
Salbutamol use (puffs/day, weeks 1e24)
LS mean change from baseline (SE) 1.4 (0.2) 1.7 (0.16) 2.4 (0.16) 2.3 (0.16)
Difference vs placebo, (95% CI) e 0.3 (0.8, 0.2) 0.9*
(1.4, 0.4)
0.8*
(1.3, 0.3)
UMEC/VI vs individual components, (95% CI) e 0.6z
(1.0, 0.1)
0.1 (0.3, 0.5) e
Time to first COPD exacerbation
HR vs placebo (95% CI) e 0.6z (0.4, 1.0) 0.7 (0.4, 1.1) 0.5y (0.3, 0.8)
*p  0.001; yp  0.01; zp < 0.05.
TDI, transition dyspnoea index; LS, Least squares; SE, standard error; CI, confidence interval; SOBDA, shortness of breath with daily
activities; OR, odds ratio; SGRQ, St. George’s respiratory questionnaire; COPD, chronic obstructive pulmonary disease; HR, hazard ratio;
UMEC/VI, umeclidinium/vilanterol.
a Response is defined as a difference between mean post-treatment SOBDA score and baseline SOBDA score of 0.1.
b Response is defined as an SGRQ total score of 4 units below baseline (score on Day 1) or lower.
Efficacy and safety of UMEC/VI in patients with COPD 1543Pharmacokinetics
Population PK analyses indicated no difference in the
systemic exposure of UMEC 62.5 mcg or VI 25 mcg when
administered as monotherapy compared with UMEC/VI
62.5/25 mcg.
Safety
The incidence of treatment-emergent AEs (TEAEs) was
similar across treatment groups (Table 3). The most
frequent TEAEs were: headache, nasopharyngitis, upper
respiratory tract infection and cough; incidences were
similar across treatment groups (Table 3). AEs that led to
study withdrawal were infrequent (active treatment
groups: 6e8%; placebo: 3%), as were serious AEs (SAEs;
active treatment groups: 5e6%; placebo: 3%) (Table 3). The
only SAE or AE leading to study withdrawal in 1% ofpatients in any treatment group was related to worsening
COPD. Fatal AEs occurred in 9 patients: 3 in the VI
25 mcg group (sudden death, COPD exacerbation, COPD
exacerbation/renal failure), 3 in the UMEC/VI 62.5/25 mcg
group (COPD exacerbation/respiratory failure, myocardial
infarction, unknown cause) and 3 in the UMEC 62.5 mcg
group (COPD/acute respiratory failure, sudden death,
cholecystitis and peritonitis).
No clinically meaningful changes were observed in vital
signs, 12-lead ECG and 24-h Holter ECG parameters, or
clinical laboratory tests for UMEC/VI 62.5/25 mcg, UMEC
62.5 mcg and VI 25 mcg, compared with placebo. The
overall incidence of patients with one or more abnormal,
clinically significant, post-baseline 12-lead ECG result
was similar across active treatment groups (18e22%) and
placebo (22%).
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Figure 4 Least squares (LS) mean transition dyspnoea index
focal score (intent-to-treat population). CI Z confidence in-
terval; UMEC Z umeclidinium bromide; VI Z vilanterol. Anal-
ysis performed using a repeated measures model with
covariates of treatment, baseline dysnpoea index focal score,
smoking status, center group, Day, Day by baseline dysnpoea
index focal score, and Day by treatment interactions.
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This clinical trial was the first to evaluate the efficacy and
safety of the long-acting bronchodilator combination
UMEC/VI 62.5/25 mcg when administered once-daily for 24
weeks in patients with COPD. Compared with UMEC
62.5 mcg and VI 25 mcg monotherapies, UMEC/VI 62.5/
25 mcg was shown to provide significant improvements in
pre-dose trough FEV1, as well as improvements in 0e6 h
weighted-mean FEV1, These benefits were substantial, with
a peak FEV1 increase from baseline of 0.273 L following the
first dose of UMEC/VI 62.5/25 mcg. These benefits were
also maintained for the duration of the study with no evi-
dence of tolerance. Treatment improvements with UMEC/Table 3 Adverse events; n (%).
On-treatment AEs
Post-treatment AEs
On-treatment SAEs
Post-treatment SAEs
AEs leading to withdraw/discontinuation of study medicationa
Fatal SAEs
AEs occurring in 3% of patients in any treatment group
Headache
Nasopharyngitis
Upper respiratory tract infection
Cough
Oropharyngeal pain
Back pain
Chronic obstructive pulmonary disease
Arthralgia
On-treatment AEs were defined as those occurring with an onset on or
the date of the last recorded dose of study drug. Post-treatment AEs
the date of the last recorded dose of study drug.
AEs, adverse events; SAEs, serious adverse events; UMEC/VI, umeclid
a Includes both on- and post-treatment AEs.VI 62.5/25 mcg compared with UMEC 62.5 mcg and VI
25 mcg monotherapies at Day 169 (0.052 L and 0.095 L for
trough FEV1; 0.092 L and 0.120 L for 0e6 h weighted-mean
FEV1) at study conclusion were of a magnitude considered
clinically meaningful in COPD [22]. Overall, the lung
function findings demonstrate that both UMEC 62.5 mcg and
VI 25 mcg are efficacious compared with placebo and that
both contribute to the bronchodilator efficacy of UMEC/VI
62.5/25 mcg over the entire 24-h dosing interval, showing
that both are effective bronchodilators suitable for once-
daily dosing.
The findings for the symptom and health-related
quality of life (HRQoL) measures indicate that the
benefits of UMEC/VI 62.5/25 mcg on lung function
translated into subjective symptomatic improvements that
were noticeable to the study participants. Throughout the
study, UMEC/VI 62.5/25 mcg improved dyspnoea compared
with placebo, as demonstrated by treatment differences in
TDI score that exceeded 1.0 unit (considered the minimal
clinically-important difference [MCID] for this measure)
[21]. These findings were consistent with improvements in
dyspnoea associated with activities of daily living, as
assessed by the SOBDA questionnaire; SOBDA is a daily,
patient-reported outcome measure that evaluates changes
in the ability to carry out daily activities [19]. Additionally,
reductions in rescue use further support that UMEC/VI
treatment results in noticeable improvements in patients
with COPD. Improvements in HRQoL with UMEC/VI 62.5/
25 mcg treatment were indicated by improvements in SGRQ
score that exceed the MCID of 4 units compared with
placebo [20]. Overall, treatment differences between
UMEC/VI 62.5/25 mcg and both UMEC 62.5 mcg and VI
25 mcg monotherapies were not as clearly defined
for health outcomes measures as they were for lung
function assessments. Nevertheless, numerically largerPlacebo
(N Z 280)
UMEC 62.5
(N Z 418)
VI 25
(N Z 421)
UMEC/VI 62.5/25
(N Z 413)
130 (46%) 216 (52%) 204 (48%) 212 (51%)
5 (2%) 15 (4%) 19 (5%) 10 (2%)
9 (3%) 27 (6%) 24 (6%) 21 (5%)
0 5 (1%) 4 (<1%) 2 (<1%)
9 (3%) 34 (8%) 24 (6%) 23 (6%)
0 3 (<1%) 3 (<1%) 3 (<1%)
26 (9%) 32 (8%) 25 (6%) 35 (8%)
16 (6%) 29 (7%) 26 (6%) 39 (9%)
14 (5%) 21 (5%) 18 (4%) 13 (3%)
7 (3%) 16 (4%) 15 (4%) 6 (1%)
4 (1%) 6 (1%) 14 (3%) 13 (3%)
7 (3%) 8 (2%) 7 (2%) 13 (3%)
3 (1%) 12 (3%) 8 (2%) 7 (2%)
3 (1%) 12 (3%) 2 (<1%) 4 (<1%)
after the date of the first dose of study drug, and up to 1 day after
were defined as those with an onset starting 2 days or more after
inium/vilanterol.
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UMEC/VI 62.5/25 mcg.
Although consistent with previous studies showing
reductions in exacerbations with long-acting bronchodilator
treatment [23,24], this study was not designed to examine
treatment effects on COPD exacerbations. Yet, time to
first exacerbation (an important measure of potential
effectiveness in COPD patients) showed that the risk of a
COPD exacerbation was lower with UMEC/VI 62.5/25 mcg,
UMEC 62.5 mcg and VI 25 mcg vs placebo, suggesting a
potential benefit for each active treatment. Additional
studies are required to fully evaluate the effect of UMEC/VI
62.5/25 mcg on the annual rate of exacerbations (particu-
larly in patients most at risk) relative to long-acting
bronchodilator monotherapy.
Class-effects such as, tremor, blood pressure changes,
tachycardia, arrhythmias, and palpitations associated with
high doses of LABAs [25,26] were not observed at higher
incidences with UMEC/VI 62.5/25 mcg or VI 25 mcg
compared with placebo. Additionally, the incidence of AEs
consistent with anticholinergic effects, such as dry mouth,
gastrointestinal events (e.g. constipation), ocular events
(e.g. blurred vision, glaucoma), tachycardia and urinary
retention [27] were low (<3%) and similar with UMEC/VI
62.5/25 mcg, UMEC 62.5 mcg and placebo. These findings
are consistent with an evaluation of a higher dose of UMEC/
VI (500/25 mcg), which showed a low incidence of
anticholinergic-related AEs (2%) and no evidence of
clinically relevant treatment effects on ECG, vital signs, or
laboratory assessments compared with placebo over 4
weeks [28]. In previous dose-ranging studies of UMEC, an
increased incidence of potentially drug-related effects such
as dry mouth and cough were observed at doses of 250 mcg
and higher [12,29] and dose-ranging evaluations of VI (up to
50 mcg) in COPD and asthma have shown VI to have a safety
and tolerability profile similar to placebo [13,30]. The
results presented here confirm and extend these findings
over a longer treatment duration, with a low incidence of
anticholinergic- or b-agonist-associated AEs reported for
UMEC/VI 62.5/25 mcg treatment. Further, no clinically
significant treatment-related changes were reported for
blood pressure, heart rate or QT interval and no apparent
treatment differences for abnormal 12-lead ECG findings
were observed for any of the active treatments.
There are limitations to the interpretation of data from
this study. There was no head-to-head comparison with an
approved LAMA or LABA monotherapy. There are also
no approved LAMA/LABA combination products available
for comparison. Concomitant inhaled corticosteroid or
bronchodilator therapies (e.g. rescue salbutamol) were
permitted during the study, representing real-world
treatment scenarios. However, these concomitant treat-
ments are unlikely to have influenced clinical outcomes
when used in these doses or regimens (e.g. lower salbuta-
mol use than indicated for bronchospasm [31]), particularly
as their administration was similarly distributed between
all study groups, including placebo.
The results of this study demonstrate that UMEC/VI
62.5/25 mcg provides more effective treatment than UMEC
62.5 mcg or VI 25 mcg monotherapies over 24 weeks in
patients with COPD, with a similar tolerability and safety
profile. Both UMEC 62.5 mcg and VI 25 mcg were shown tobe efficacious compared with placebo. The study findings
confirm the rationale for the development of a combination
long-acting bronchodilator therapy utilising medications
with distinct and complementary mechanisms of action,
and the convenience of a once-daily dosing regimen further
supports UMEC/VI 62.5/25 mcg as a maintenance treatment
for COPD.
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